Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Sold by Janney Montgomery Scott LLC

Janney Montgomery Scott LLC decreased its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 13.3% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 14,053 shares of the medical equipment provider’s stock after selling 2,157 shares during the quarter. Janney Montgomery Scott LLC’s holdings in Lantheus were worth $1,542,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of LNTH. Envestnet Portfolio Solutions Inc. lifted its position in Lantheus by 9.0% in the first quarter. Envestnet Portfolio Solutions Inc. now owns 5,369 shares of the medical equipment provider’s stock worth $334,000 after purchasing an additional 442 shares during the period. Headlands Technologies LLC bought a new position in Lantheus during the first quarter valued at about $105,000. Russell Investments Group Ltd. grew its holdings in Lantheus by 10.4% during the first quarter. Russell Investments Group Ltd. now owns 37,708 shares of the medical equipment provider’s stock worth $2,347,000 after acquiring an additional 3,560 shares during the period. ProShare Advisors LLC raised its position in Lantheus by 4.7% in the first quarter. ProShare Advisors LLC now owns 15,567 shares of the medical equipment provider’s stock worth $969,000 after acquiring an additional 698 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System lifted its holdings in Lantheus by 8.6% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 21,088 shares of the medical equipment provider’s stock valued at $1,313,000 after acquiring an additional 1,670 shares during the last quarter. 99.06% of the stock is owned by institutional investors and hedge funds.

Lantheus Price Performance

Shares of Lantheus stock opened at $80.84 on Friday. The stock has a 50-day simple moving average of $105.46 and a 200-day simple moving average of $96.17. Lantheus Holdings, Inc. has a 52-week low of $50.20 and a 52-week high of $126.89. The firm has a market cap of $5.62 billion, a price-to-earnings ratio of 13.45 and a beta of 0.51.

Wall Street Analysts Forecast Growth

LNTH has been the topic of several recent research reports. Redburn Atlantic began coverage on shares of Lantheus in a research note on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 price objective on the stock. JMP Securities dropped their price target on Lantheus from $125.00 to $112.00 and set a “market outperform” rating on the stock in a report on Thursday, November 7th. StockNews.com upgraded Lantheus from a “hold” rating to a “buy” rating in a research report on Friday, November 8th. B. Riley lifted their target price on Lantheus from $105.00 to $146.00 and gave the stock a “buy” rating in a report on Thursday, July 25th. Finally, Truist Financial reaffirmed a “buy” rating and set a $120.00 target price (down from $135.00) on shares of Lantheus in a report on Friday, November 8th. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat, Lantheus currently has a consensus rating of “Moderate Buy” and a consensus target price of $122.50.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.